In sickle cell disease (SCD), 'disease severity' associates with increased RBC adhesion to quiescent endothelium, but the impact on activated endothelium is not known. Increased concentrations of free heme result from intravascular hemolysis in SCD. Heme is essential for aerobic metabolism and plays an important role in numerous biological processes. Excess free heme induces reactive oxygen species generation and endothelial activation, which are associated with cardiovascular disorders including atherosclerosis, hypertension, and thrombosis. Here, we utilized an endothelialized microfluidic platform (Endothelium-on-a-chip) to assess adhesion of sickle hemoglobin-containing red blood cells (HbS RBCs), from adults with homozygous SCD, to hemeactivated human endothelial cells (EC) in vitro. Confluent EC monolayers in microchannels were treated with pathophysiologically relevant levels of heme in order to simulate the highly hemolytic intravascular milieu seen in SCD. RBC adhesion to heme-activated ECs varied from subject to subject, and was associated with plasma markers of hemolysis (LDH) and reticulocytosis, thereby linking those RBCs that are most likely to adhere with those that are most likely to hemolyze.
conditions in vitro. 15, 16 Such endothelialized systems have recently been designed and implemented to simulate vaso-occlusion in SCD and measure protein expression in response to changes in wall shear stress. 17, 18 However, we are unaware of previous studies in which a microfluidic platform has been employed to systematically study the association of RBC adhesion to activated endothelium with clinical phenotype. This is in part because of the technical challenges that are associated with the manufacture of endothelialized microfluidic systems in a consistent and high-throughput manner, which can then be implemented in a large clinical population. Here, we introduce a new microfluidic approach to the fabrication of microfluidic channels seeded with human endothelial cells utilizing a lamination-based technique and laser micro-machined components (Endothelium-on-a-chip). This allowed us to assess HbS RBC adhesion to human endothelial cells that were stimulated with pathophysiologic levels of heme in a clinically diverse adult SCD population.
Adhesion of HbS RBCs to the endothelium and associated adhesion molecules is heterogeneous and linked to disease severity as was shown by us and others. [19] [20] [21] [22] [23] This heterogeneity exists within an individual patient due to distinct RBC subpopulations with impaired biophysical properties as well as at a population level in which individuals with SCD present varying clinical phenotypes. [24] [25] [26] [27] Nonetheless, heterogeneous adhesion of RBCs in a SCD population has yet to be adequately addressed, perhaps because many important pathophysiologic studies have been conducted using inbred sickle cell mice with
RBCs that are homogeneous within the population. 11, 28, 29 In contrast, humans with SCD exhibit a more heterogeneous distribution of RBCs, as we have previously shown, 22, 27, 30, 31 likely because of confounding co-inherited disease-modifying genes. We hypothesized that endothelial activation in SCD is associated with enhanced RBC adhesion in a range that reflects clinical heterogeneity and disease severity.
Our integrated clinical Endothelium-on-a-chip microfluidic approach allowed us to determine the impact of individual pathophysiologic components in a model incorporating only human-derived cells, e.g., HbS
RBCs and activated endothelial cells. At its simplest, these are the variables at play in the adhesion of an RBC to the endothelium. Here, we hold one of those two variables, activated endothelium, constant through treating (heme-activated) cultured endothelial cells in a consistent manner. We interrogate RBC adhesion to this activated endothelium using clinical blood samples acquired from adults with SCD who are followed in our clinic, thereby examining the contribution to abnormal adhesion at an activated endothelium that is made by the RBC. In this publication, we highlight for the first time the correlative relationship between RBC adhesion to heme-activated endothelium and clinical phenotypes associated with a hemolytic plasma milieu in vivo.
| M E T H O D S

| Subjects and sample collection
Sickle blood samples were obtained from de-identified adult subjects (18 years) with homozygous (HbSS) SCD at University Hospitals CWRU (Cleveland, OH), under an Institutional Review Board (IRB) approved protocol. All samples were collected in ethylenediaminetetraacetic acid (EDTA)-containing tubes, and subjects' hemoglobin types were confirmed by high-performance liquid chromatography (HPLC).
Only subjects infected with HIV or hepatitis C were ineligible for this study. The clinical phenotypes of the study population are summarized in Supporting Information Table S1 .
2.2 | Endothelium-on-a-chip fabrication and endothelialization of microfluidic channels
Microfluidic channels were fabricated using a lamination technique, as previously described. 22 Briefly, the channel geometry was determined by laser micro-machined double-sided adhesive (DSA) films that were placed between a top polymethyl methacrylate (PMMA) cap and bottom microscope glass slide, forming a uniform flow domain ( Figure 1A ).
The assembled microchannels were rinsed serially with PBS, 100%
ethanol, and GMBS following a 20-minute incubation. Thereafter, another washing step was performed using 100% ethanol and PBS before loading the microchannels with a fibronectin solution at a concentration of 0.2 mg/mL. Fibronectin-loaded microchannels were incubated at 378C for 1 h for complete protein immobilization on the GMBS-functionalized surface. To prepare the Endothelium-on-a-chip microchannels, human umbilical vein endothelial cells were seeded into fibronectin-coated microchannels at a density of 8 3 10 6 cells/mL and incubated for 4 hours at 378C and 5% CO 2 to allow cell attachment and spreading, while replacing the culture medium in the microchannels every hour (Supporting Information Figure S1A ). An initial seeding density of 1 3 10 6 cell/mL did not yield a confluent monolayer over the microchannel surface after 4 hours (Supporting Information Figure S2 ), hence we consistently used a seeding density of 8x10 6 cells/mL throughout this study.
| Heme activation of endothelial cells
Prior to blood perfusion, immobilized human endothelial cells (EC) were incubated with 20 mM or 40 mM heme-containing RPMI-1640 for 60 minutes in 378C ( Figure 1B ). The control microchannels were loaded with heme-free RPMI-1640 and incubated under the same conditions. were carried out using ImageJ software. 32 
| Statistical methods
Data acquired in this study were reported as mean 6 standard error of the mean (SEM). All statistical analyses were carried out using Minitab 18 Software (Minitab Inc., State College, PA). Data were analyzed for normality followed by either non parametric Mann-Whitney U test or parametric one-way ANOVA. Statistical significance was set at 95%
confidence level for all tests (P < 0.05). 
| R E S U LTS
| Heme activation mediates the expression of P-selectin and VCAM-1 on ECs
Endothelial expression of P-selectin ( Figure 2B ) and VCAM-1 ( Figure   2C ) significantly increased with heme activation (P < 0.05, one-way ANOVA), for VCAM-1 in a concentration dependent manner.
| HbS RBC adhesion to immobilized ECs
More HbS RBCs adhered to heme-activated than quiescent ECs, with significant differences observed at both 20 mM and 40 mM levels of heme activation ( 
| Clinical implications of heme-mediated RBC adhesion to ECs
To determine whether subjects' clinical phenotypes impacted adhesion profiles of their HbS RBCs, we analyzed univariate models via the k- . Four out of seven subjects with no recent Tx record were on hydroxyurea (HU) while the other three subjects were on supportive care at the time of sample collection. Two out of nine subjects with a recent Tx record were also receiving HU therapy. Only one subject out of seven who did not have recent Tx was in Group 2 whereas that ratio was eight out of nine among the subjects with recent Tx. N 5 7 for the no recent Tx subject group and N 5 9 for the recent Tx subject group. The horizontal brackets between Groups 1 and 2 indicate statistically significant difference. N represents the number of subjects [Color figure can be viewed at wileyonlinelibrary.com]
variables. Accordingly, we found that one out of seven subjects in Table S2 .
| DISCUSSION
In this study, we developed an Endothelium-on-a-chip microfluidic adhesion assay seeded with human ECs to study HbS RBC adhesion in a clinically relevant manner. Earlier studies employing endothelialized platforms to probe RBC adhesion in vitro largely depended on static incubation of RBCs within microfluidic chambers, where the effect of micro-physiological flow conditions on the adhesion dynamics were negated. [19] [20] [21] [33] [34] [35] [36] Recently, a number of endothelialized microfluidic systems have been designed and implemented to study various pathophysiological conditions. 15, 17, 18, [37] [38] [39] [40] The main advantage of these systems stems from their ability to provide a precisely controlled flow environment, with which to better mimic the physiological milieu and with which to impose pathological scenarios. Although recent advancements in microsystem development have significantly contributed to our understanding of various hematologic diseases, the focus on technical aspects of fabrication and endothelialization has hindered the use of these platforms in a more clinically-useful fashion. Therefore, in this work, we adopted a lamination-based fabrication technique using laser micro-machined parts in constructing the micro-devices that can be performed within 5 minutes. Additionally, we optimized the microchannel endothelialization process to allow confluent EC monolayer growth following a 4-hour incubation, which facilitated the production of endothelialized microchannels in large quantities and timely manner for a clinically relevant use.
Further, the large-scale design of this Endothelium-on-a-chip microfluidic platform affords a significantly greater surface area compared to currently available endothelialized microfluidic systems (i.e. In our model, we found consistent expression of VE-cadherin at cell-to-cell junctions after a static incubation of ECs for 4 hours, indicating the maintenance of endothelial cell functionality and integrity. [41] [42] [43] [44] [45] [46] We treated these monolayers with pathological levels of heme in order to mimic the highly hemolytic microvascular conditions often triggered in SCD patients due to the short lifespan of HbS RBCs. 47, 48 Plasma heme levels, and by extension serum LDH levels, are significantly greater in these patients compared to healthy controls. 49 Earlier studies reported plasma heme concentrations up to 20 mM in a group of SCD subjects at steady state, but this can increase further during a VOC due to significantly shortened RBC lifespan and excessive hemolysis. [50] [51] [52] [53] Therefore, we used heme concentrations that simulate physiological and pathophysiological conditions in SCD, and assessed HbS-containing RBC adhesion to both quiescent and activated ECs.
In an early study, it has been shown that heme treatment of endothelial cells induced the expression of adhesion molecules VCAM-1, ICAM-1, and E-selectin due to increased oxidative stress. 10 More recently, the role of toll like receptor 4 (TLR4) in heme-induced endothelial activation was identified, where the activation of TLR4 signaling resulted in increased expression of VCAM-1, ICAM-1, E-selectin, Pselectin, IL-1, IL-6, IL-8, and tissue factor via a pathway involving the activation of NF-jB phospho-p65. 11 This mechanism explains that the activation of TLR4 signaling leads to the production of ROS, which triggers degranulation of Weibel-Palade bodies and rapid immobilization of P-selectin and vWF on the endothelial surface. 11 However, the pres- High levels of LDH, and by inference heme, as well as ARCs in SCD have been previously linked to disease severity. 49, 58, [62] [63] [64] [65] However, the dynamics of RBC adhesion and its relationship to ongoing hemolysis has not been well understood. Although the toxic byproducts, including cell-free heme, accumulate in plasma during intravascular hemolysis and lead to an inflamed and highly activated endothelial lining, whether this results in uniform elevation in RBC adhesion to the endothelium was not clear. In our earlier work 22, 23 , we showed that RBCs from subjects with higher LDH and reticulocytes adhered to immobilized laminin more significantly, in both normoxic and hypoxic conditions, compared with the subjects who had lower hemolytic biomarker levels, revealing that RBCs that hemolyze may be more adhesive (or vice versa), independent from the deleterious impacts of hemolysis on the endothelium. Similarly, our results in this work suggest that RBCs from subjects with a more severe hemolytic phenotype have greater adhesion to heme-activated ECs, supporting the key contribution of adhesive RBCs to the "hyperhemolysis paradigm" in SCD. [66] [67] [68] Our results collectively suggest that the degree of RBC adhesion differs significantly among individuals with SCD, and may be in strong association with hemolysis, despite the presence of a consistently activated endothelium with a pro-inflammatory phenotype.
Subjects with markedly increased levels of LDH and of ARC, associated with greater RBC adhesion, also had significantly higher WBC [73] [74] [75] [76] [77] [78] Moreover, the interplay between these cellular components is often magnified by complex plasma proteins that may act as molecular bridges between circulating blood cells and the activated endothelial layer. 78 Therefore, having a thorough grasp of underlying VOC mechanisms in SCD requires the simultaneous examination of interactions between all these cellular components as well as the pertinent molecular pathways.
However, this study is principally focused toward better understanding the isolated role of RBCs, which are highly heterogeneous within the SCD population, and adhesion to activated human ECs. Indeed, our findings highlight the importance of heterogeneous RBC adhesion to heme-activated human ECs, in particular the strong association of this adhesion with clinical phenotypes. In addition, removal of plasma from blood samples allowed us to precisely control the extent of hemedriven endothelial activation, without additional interference by cytokines or other endothelial-activating agents in the plasma that may have varied from subject to subject.
In conclusion, we have designed and implemented an endothelial- 
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